Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (71-80 of 251) with videos related to

Pageof 26
Sort By:
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Transplantation and Cellular Therapy|August 14, 2022
Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHDColombe Saillard, Pierre-Henri Legal, Sabine Furst, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
Journal of Geriatric Oncology|September 23, 2023
Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG)Martine Extermann, Andrew Artz, Maite Antonio Rebollo, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter studyNorbert Vey, Andre Bosly, Agnes Guerci, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Critical Care (London, England)|February 20, 2008
Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factorDjamel Mokart, Eric Kipnis, Pierre Guerre-Berthelot, et al.
Cancer|October 26, 2012
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseasesRoberto Crocchiolo, Benjamin Esterni, Luca Castagna, et al.
Pageof 26

Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
Haematologica|October 8, 2008
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemiaJean-Valère Malfuson, Anne Etienne, Pascal Turlure, et al.
Transplantation and Cellular Therapy|August 14, 2022
Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHDColombe Saillard, Pierre-Henri Legal, Sabine Furst, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
Journal of Geriatric Oncology|September 23, 2023
Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG)Martine Extermann, Andrew Artz, Maite Antonio Rebollo, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter studyNorbert Vey, Andre Bosly, Agnes Guerci, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Critical Care (London, England)|February 20, 2008
Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factorDjamel Mokart, Eric Kipnis, Pierre Guerre-Berthelot, et al.
Cancer|October 26, 2012
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseasesRoberto Crocchiolo, Benjamin Esterni, Luca Castagna, et al.
Pageof 26